Mitotane-induced dyspnoea: an unusual side effect

BMJ Case Rep. 2018 Sep 1:2018:bcr2018225490. doi: 10.1136/bcr-2018-225490.

Abstract

Mitotane is a cytostatic antineoplastic agent that is used in the treatment of adrenocortical carcinoma and Cushing's syndrome. The commonly reported side effects associated with mitotane are anorexia, nausea, vomiting, diarrhoea, decreased memory, rash, gynaecomastia, arthralgias and leucopenia. We present a case of a 68-year-old female who developed gradual dyspnoea concurrent with the use of mitotane for the treatment of adrenocortical carcinoma. To the best of our knowledge and literate review, this is the first reported case of dyspnoea associated with the use of this medication. The purpose of this case report is to raise awareness about this uncommon adverse effect of mitotane that may have gone unrecognised on postmarketing surveillance because of under-reporting, lack of case follow-up or other comorbidities masking shortness of breath.

Keywords: adrenal disorders; drugs: respiratory system; unwanted effects / adverse reactions.

Publication types

  • Case Reports

MeSH terms

  • Adrenal Cortex Neoplasms / drug therapy*
  • Adrenocortical Carcinoma / drug therapy*
  • Aged
  • Antineoplastic Agents, Hormonal / adverse effects*
  • Diagnosis, Differential
  • Drug-Related Side Effects and Adverse Reactions / etiology
  • Dyspnea / chemically induced*
  • Female
  • Humans
  • Mitotane / adverse effects*

Substances

  • Antineoplastic Agents, Hormonal
  • Mitotane